Medical devices & diagnostics · Surgical robotics
Revolve Surgical
A Toronto company building a laparoscopic robot that clamps to the operating table instead of filling the room. The FDA cleared its first configuration in October 2025. The first human case has not been reported.
The arm that clamps to the table
A reusable arm mounts to the rail of an operating table. The surgeon takes hold of an instrument handle, moves it where the work is, and lets go. The arm holds that position and cancels the weight of the instrument. No console across the room, no cart beside the bed. The surgeon never leaves the patient.
That is the machine the FDA cleared on October 3, 2025, described in the agency’s words rather than the company’s. The 510(k) summary puts the control scheme in one line: “The device operates under the direct control of the surgeon to manipulate tissues during surgery.”
Revolve calls the design zero footprint. The argument is that a robot adding no floor space, no cart and no extra staff can reach where robots have not: the abdominal surgeries done outside hospitals, and the public systems that never bought one at all.
The gap it is aimed at
Robotic assistance is still rare. Axel Krieger, the roboticist behind the STAR system, has said that of more than 300 million major surgical procedures a year, just over one percent use robotic assistance. The reason is no mystery. Ambulatory Surgery Center News reports that a da Vinci system, the category leader, costs between $1 million and $2.5 million depending on model and configuration.
Two things changed recently. Medicare expanded which procedures ambulatory surgery centers can bill for, effective January 1, 2026, which pays nothing extra for robotics but lets more cases leave the hospital. And smaller platforms arrived aimed at exactly those rooms: Distalmotion’s Dexter, Moon Surgical’s Maestro, CMR Surgical’s Versius Plus, Medtronic’s Hugo.
Moon Surgical is not only a competitor. Maestro is the reference device Revolve cited in its own FDA submission, alongside its predicate, the Human Xtensions HX Device. Distalmotion, working the same market, raised a $150 million Series G and about $400 million in total, according to its chief executive. Revolve reached its clearance on a tiny fraction of that.
Four trainees from a SickKids lab
The founders met in 2016 doing research at the surgical robotics labs at the Hospital for Sick Children in Toronto, according to BetaKit’s account of their Y Combinator demo day. The Posluns Centre at SickKids lists them on its alumni roll: Alex Gordon, a PhD trainee, and Rami Saab, a master’s trainee, each tagged a founder of Revolve Surgical, with Matthew Kang and Peter Francis as master’s trainees.
The company tells the same story in its own words. Working alongside existing robots in that lab, the founders concluded that the binding limit was not dexterity but access, and that the fix was to keep the surgeon at the table and drop teleoperation entirely.
Revolve Surgical Inc. was incorporated on June 14, 2019. It went through Y Combinator’s Summer 2021 batch, and at demo day claimed a system one percent the size and cost of competing products, developed with 50 surgeons, with animal testing already complete.
A clearance held for five months
The submission reached the FDA on December 23, 2024. A final amendment arrived on September 5, 2025. The clearance letter is dated October 3, 2025, signed by an acting assistant director in the Division of General Surgery Devices.
Revolve announced it on March 17, 2026, and several trade outlets then reported that date as the clearance date itself. One wrote that “On March 17, 2026, the company earned FDA 510(k) clearance for a table-mounted surgical robot with a zero-footprint design.” The FDA database says otherwise. Nothing in the record explains the gap.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| FDA 510(k) K243968 | Received Dec 23, 2024, cleared Substantially Equivalent Oct 3, 2025. Class II, 21 CFR 876.1500, product code GCJ. Predicate: HX Device, Human Xtensions (K173919). Reference: Maestro, Moon Surgical (K221410). Traditional 510(k), not third party reviewed. | Public record |
| What is actually cleared | One reusable system arm mounted to the table, plus a single use instrument, handle and drape. The listed instrument is a straight, single action needle holder inserted through a 5mm trocar. Indication: assisting control of a Revolve laparoscopic instrument for endoscopic manipulation of tissue, including approximation, ligation and suturing, in laparoscopic general surgery. | Public record |
| Testing behind the clearance | Software verification, electrical safety and EMC, reprocessing and shelf life, biocompatibility, human factors, and bench tests of arm positioning, gravity compensation, port alignment, braking and emergency stop. Abdominal phantoms were used where necessary. No animal or clinical data appears in the summary. | Public record |
| Date of clearance | FDA decision date Oct 3, 2025. Company announcement and trade coverage Mar 17, 2026, with at least one outlet stating the clearance was earned on Mar 17, 2026. | Differs from the record |
| First in human study | NCT07455487, sponsored by Unity Health Toronto with Revolve as collaborator, first posted Mar 6, 2026. Three adults aged 21 to 40 with uncomplicated appendicitis, no comorbidities, no medications. Camera only in case one, camera plus one instrument in case two, camera plus two in case three. Primary outcome: completion without conversion. Still listed as not yet recruiting, estimated start Apr 1, 2026. | Public record |
| Health Canada licence | A company search of the Medical Devices Active Licence Listing for Revolve returns nothing, on Sep 22, 2026. The same search for Intuitive returns Intuitive Surgical Inc. The Toronto study describes the system as investigational. | Not found |
| Wristed instruments, modular arms, AI | The website markets 5mm wristed instruments, modular arms for tissue retraction and advanced vision, natural force feedback, and data analytics with AI. None of these appear in the cleared device description. | Company-stated |
| Size and cost | One percent the size and cost of competing systems, and an order of magnitude less size, cost and training. Repeated in 2021 and 2024 coverage. No price has been published. | Company-stated |
| Peer reviewed papers | None found in PubMed for the company or the device as of Sep 22, 2026. | Not found |
Read plainly: the clearance is real, and the device that is cleared is narrower than the device that is marketed. One reusable arm, one straight needle holder, one 5mm port, validated on bench rigs and abdominal phantoms. The wristed instruments, the retraction and vision arms and the AI are product plans, not cleared features, and Revolve has said as much by telling reporters it expects a wider clearance before it launches commercially. The first patient has not been reported.
What to watch
- The Unity Health appendectomy series. The registry has shown an April 2026 estimated start and a not yet recruiting status since March 2026.
- The second 510(k). Revolve has told reporters it expects expanded clearance for all laparoscopic surgery ahead of commercial launch.
- A Health Canada licence. The company, the hospital and the first patients are all in Ontario, and the device is not licensed there.
- Whether wristed instruments reach a submission. They sit at the centre of the marketing and are absent from the cleared system.
- A priced financing. The last publicly recorded capital events are accelerator and grant entries, not a venture round.
In their words
“Technology, particularly AI, is moving faster than ever before, and in most industries if you have a computer or smartphone you can access it. But in surgery, there’s no universally accessible platform.”
Alex Gordon, co-founder, in the FDA clearance announcement, March 2026 · Company release
“As of today, there’s a new ‘personal’ surgical platform, small enough for one-person setup and operation.”
Matthew Kang, co-founder, March 2026 · Company release
“We chose to partner with Revolve Surgical because their system offers a new approach that fits into our existing practice.”
Dr. Ori Rotstein, general surgeon and VP of research and innovation, Unity Health, March 2026 · Partner-stated
“Revolve’s platform is a hybrid manual-robotic approach that aims to reduce the size, cost, and training of current surgical robots by an order of magnitude”
Alex Gordon, quoted by Newzchain, 2024 · Company-stated
“The device operates under the direct control of the surgeon to manipulate tissues during surgery.”
FDA 510(k) summary, K243968, October 2025 · Public record
“This will be the first time the device is used in patients.”
Study record NCT07455487, Unity Health Toronto, posted March 2026 · Public record
“it would be prohibitively expensive for our surgery center to spend, say, a million and a half dollars to buy a robot”
Dr. Michael Burdi, orthopedic spine surgeon, to Ambulatory Surgery Center News, 2025 · Independent
Related companies
Sources
- Public recordFDA 510(k) clearance letter and summary, K243968
- Public recordFDA 510(k) premarket notification database entry, K243968
- Public recordClinicalTrials.gov NCT07455487, first appendectomy using the Revolve arm
- Public recordHealth Canada active licence listing, queries for Revolve
- Public recordPubMed search for Revolve Surgical
- IndependentRevolve Surgical wins FDA clearance for surgical robot
- IndependentRevolve receives FDA clearance for surgical robot
- IndependentThe robot that fits where others will not
- IndependentThe 16 Canadian startups at Y Combinator Summer 2021 Demo Day
- IndependentSoft Tissue Surgical Robotics 2026
- IndependentSurgeries are moving to ASCs. Distalmotion wants its robot to drive the shift.
- IndependentThe rise of surgical robotics in ASCs
- IndependentRevolve Surgical company and funding profile
- IndependentRevolve Surgical deal history and patent activity
- IndependentRevolve Surgical total raised and patent count
- IndependentPosluns Centre team and alumni list
- IndependentRevolve Surgical: affordable robotic surgery
- CompanyRevolve Surgical website and founding story
- CompanyRevolve Surgical company page and FDA clearance post
- CompanyY Combinator company page, Summer 2021
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
